Anne F. Schott

11.6k total citations · 3 hit papers
92 papers, 7.0k citations indexed

About

Anne F. Schott is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anne F. Schott has authored 92 papers receiving a total of 7.0k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Oncology, 29 papers in Cancer Research and 25 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anne F. Schott's work include Advanced Breast Cancer Therapies (21 papers), Cancer Treatment and Pharmacology (21 papers) and Breast Cancer Treatment Studies (20 papers). Anne F. Schott is often cited by papers focused on Advanced Breast Cancer Therapies (21 papers), Cancer Treatment and Pharmacology (21 papers) and Breast Cancer Treatment Studies (20 papers). Anne F. Schott collaborates with scholars based in United States, France and Italy. Anne F. Schott's co-authors include Max S. Wicha, Celina G. Kleer, Gabriela Dontu, Julie Dutcher, Florence Monville, Emmanuelle Charafe‐Jauffret, Daniel Birnbaum, Christophe Ginestier, Suling Liu and Jocelyne Jacquemier and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Anne F. Schott

88 papers receiving 6.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome

2007 3.1k citations Anne F. Schott, Max S. Wicha et al. profile →
Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps

2016 721 citations Anne F. Schott et al. profile →
Circulating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500

2014 482 citations William E. Barlow, Gabriel N. Hortobágyi et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anne F. Schott United States	32	4.4k	2.5k	2.4k	952	898	92	7.0k
Bjørn Naume Norway	45	3.4k 0.8×	3.1k 1.2×	2.5k 1.0×	862 0.9×	1.1k 1.2×	134	6.7k
Peter Vermeulen Belgium	42	3.2k 0.7×	2.7k 1.1×	3.1k 1.3×	605 0.6×	1.1k 1.3×	142	6.6k
Mark Basik Canada	41	2.8k 0.6×	2.9k 1.2×	3.5k 1.4×	774 0.8×	1.0k 1.1×	142	7.2k
Melinda L. Telli United States	37	3.4k 0.8×	1.7k 0.7×	1.8k 0.7×	527 0.6×	1.2k 1.3×	128	5.4k
Steven Van Laere Belgium	45	2.7k 0.6×	2.5k 1.0×	2.6k 1.1×	494 0.5×	968 1.1×	161	5.6k
Francesco Bertolini Italy	57	4.2k 1.0×	2.7k 1.1×	5.0k 2.0×	1.5k 1.5×	1.2k 1.4×	244	10.5k
Priti Lal United States	34	3.0k 0.7×	2.0k 0.8×	2.5k 1.0×	1.3k 1.4×	2.4k 2.7×	128	6.7k
Mar Iglesias Spain	27	3.9k 0.9×	1.5k 0.6×	2.6k 1.1×	1.2k 1.3×	1.1k 1.2×	94	6.6k
Pnina Brodt Canada	46	2.5k 0.6×	2.2k 0.9×	3.2k 1.3×	1.1k 1.2×	689 0.8×	115	6.8k
Kunwei Shen China	37	2.7k 0.6×	2.2k 0.9×	1.6k 0.7×	573 0.6×	914 1.0×	231	5.2k

Countries citing papers authored by Anne F. Schott

Since Specialization

Citations

This map shows the geographic impact of Anne F. Schott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anne F. Schott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anne F. Schott more than expected).

Fields of papers citing papers by Anne F. Schott

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anne F. Schott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anne F. Schott. The network helps show where Anne F. Schott may publish in the future.

Co-authorship network of co-authors of Anne F. Schott

This figure shows the co-authorship network connecting the top 25 collaborators of Anne F. Schott. A scholar is included among the top collaborators of Anne F. Schott based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anne F. Schott. Anne F. Schott is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wesolowski, Robert, Hope S. Rugo, Jennifer M. Specht, et al.. (2025). Gedatolisib Combined with Palbociclib and Letrozole in Patients with No Prior Systemic Therapy for Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer. Clinical Cancer Research. 31(19). 4040–4048.

Hamilton, Erika, Rinath Jeselsohn, Sara A. Hurvitz, et al.. (2024). Abstract PS15-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, plus palbociclib in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer: phase 1b cohort. Cancer Research. 84(9_Supplement). PS15–3. 2 indexed citations

Kalinsky, Kevin, William E. Barlow, Harsh B. Pathak, et al.. (2024). Correlation of serum anti-Müllerian hormone (AMH) levels on identification of premenopausal patients (pts) with hormone receptor positive (HR+), HER2-negative, node-positive breast cancer most likely to benefit from adjuvant chemotherapy in SWOG S1007 (RxPONDER).. Journal of Clinical Oncology. 42(16_suppl). 505–505. 5 indexed citations

Hurvitz, Sara A., Anne F. Schott, X. Cynthia, et al.. (2024). Abstract PO3-05-08: Updated results from VERITAC evaluating vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in ER–positive/human epidermal growth factor receptor 2 (HER2)–negative advanced breast cancer. Cancer Research. 84(9_Supplement). PO3–5. 6 indexed citations

Rugo, Hope S., Robert Wesolowski, Erica Stringer-Reasor, et al.. (2023). 204P Phase Ib study of gedatolisib plus palbociclib and endocrine therapy in women with hormone receptor positive advanced breast cancer: Updated results in treatment naïve patients. ESMO Open. 8(1). 101393–101393. 1 indexed citations

Philipovskiy, Alexander, Anne F. Schott, Javier Cortés, et al.. (2023). 256TiP TACTIVE-E: Phase Ib study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. ESMO Open. 8(1). 101444–101444. 2 indexed citations

Patel, Monica, Jennifer Shah, Floyd J. Brinley, et al.. (2023). Investigating potential disparities in clinical trial eligibility and enrollment at anNCI‐designated comprehensive cancer center. Cancer Medicine. 12(11). 12802–12812. 3 indexed citations

Hamilton, Erika, Hyo S. Han, Anne F. Schott, et al.. (2023). 390P Vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: Update of dose escalation results from a phase I/II trial. Annals of Oncology. 34. S344–S344. 12 indexed citations

Moore, Halle C. F., William E. Barlow, George Somlo, et al.. (2021). A Randomized Trial of Fulvestrant, Everolimus, and Anastrozole for the Front-line Treatment of Patients with Advanced Hormone Receptor–positive Breast Cancer, SWOG S1222. Clinical Cancer Research. 28(4). 611–617. 8 indexed citations

10.

Goldstein, Lori J., Mauro Mansutti, Christelle Lévy, et al.. (2020). Abstract P3-11-07: A randomized phase II trial of reparixin, a CXCR1 inhibitor, in combination with paclitaxel in the treatment of mTNBC. Cancer Research. 80(4_Supplement). P3–11. 3 indexed citations

11.

Hertz, Daniel L., Kelley M. Kidwell, Feng Li, et al.. (2018). Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy. Clinical Cancer Research. 24(15). 3602–3610. 45 indexed citations

12.

Kidwell, Kelley M., et al.. (2018). Ado-Trastuzumab Emtansine-Induced Pulmonary Toxicity: A Single-Institution Retrospective Review. Case Reports in Oncology. 11(2). 527–533. 10 indexed citations

13.

Schott, Anne F., Lori J. Goldstein, Massimo Cristofanilli, et al.. (2017). Phase Ib Pilot Study to Evaluate Reparixin in Combination with Weekly Paclitaxel in Patients with HER-2–Negative Metastatic Breast Cancer. Clinical Cancer Research. 23(18). 5358–5365. 181 indexed citations

14.

Cobain, Erin F., Dan R. Robinson, Yi‐Mi Wu, et al.. (2017). Clinical application of comprehensive next generation sequencing in the management of metastatic cancer in adults.. Journal of Clinical Oncology. 35(15_suppl). 101–101. 7 indexed citations

15.

Paoletti, Costanza, Maria C. Muñiz, Dafydd G. Thomas, et al.. (2014). Development of Circulating Tumor Cell-Endocrine Therapy Index in Patients with Hormone Receptor–Positive Breast Cancer. Clinical Cancer Research. 21(11). 2487–2498. 104 indexed citations

16.

Schott, Anne F., Melissa D. Landis, Gabriela Dontu, et al.. (2013). Preclinical and Clinical Studies of Gamma Secretase Inhibitors with Docetaxel on Human Breast Tumors. Clinical Cancer Research. 19(6). 1512–1524. 209 indexed citations

17.

Henry, N. Lynn, Rong Xia, Mousumi Banerjee, et al.. (2013). Predictors of recovery of ovarian function during aromatase inhibitor therapy. Annals of Oncology. 24(8). 2011–2016. 35 indexed citations

18.

LeCarpentier, Gerald L., et al.. (2009). Spatial registration of temporally separated whole breast 3D ultrasound images. Medical Physics. 36(9Part1). 4288–4300. 8 indexed citations

19.

Nguyen, Anne, Vered Stearns, Anne F. Schott, et al.. (2007). Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen. Clinical Pharmacology & Therapeutics. 83(5). 702–710. 31 indexed citations

20.

Suh, W. Warren, Anne F. Schott, James A. Hayman, et al.. (2004). A Phase I Dose Escalation Trial of Gemcitabine with Radiotherapy for Breast Cancer in the Treatment of Unresectable Chest Wall Recurrences. The Breast Journal. 10(3). 204–210. 11 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact